Current Headlines

  1. Alkermes Starts Phase I Study Of Potential MS Treatment
    7/22/2014

    Dublin drug manufacturer Alkermes has initiated a phase I clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule intended for the treatment of multiple sclerosis (MS). The launch of this trial could hopefully lead to some good news for those 400,000 individuals in the U.S. and 2.5 million people worldwide affected by MS.

  2. AbbVie Acquires Shire To Reincorporate In U.K.
    7/21/2014
    AbbVie and Shire announced in a cooperation agreement that AbbVie has agreed to acquire Shire in a $54 billion takeover deal. The acquisition of the U.K. pharmaceutical company will allow AbbVie to reincorporate in the U.K. and lower its tax bill from 23 percent in the U.S. to 13 percent in the U.K., according to The New York Times. The deal follows a recent trend of U.S. firms reincorporating in the U.K. to lower taxes, although top executives including AbbVie’s CEO Richard A. Gonzalez, have denied that the primary reason is financial. Rather, he says the Shire acquisition was a strategic fit.
  3. Salix Gets FDA OK For Rare Genetic Disease Drug
    7/21/2014
    The U.S. Food and Drug Administration (FDA) announced that it has approved Salix Pharmaceuticals and Pharming Group’s Ruconest as the first recombinant C1-Esterase Inhibitor for the treatment of acute attacks in patients with hereditary angioedema (HAE).
  4. French Drugmaker Ipsen Starts Operation In Cambridge, MA
    7/21/2014

    The French pharmaceutical company Ipsen joins the growing number of pharmaceutical companies that has planted roots in Cambridge, Massachusetts with the launch of Ipsen Bioscience.

  5. Life Science Leader Chief Editor To Co-Chair BIO International Program Committee
    7/18/2014

    Life Science Leader magazine’s Chief Editor, Rob Wright, has been invited to serve as educational program planning committee co-chair for the 2015 BIO International Convention,  

  6. Scientists Design Immunosignatures As Early Cancer Diagnostic
    7/18/2014
    A team of scientists from Arizona State University’s Biodesign Institute, under the leadership of Phillip Stafford, has designed an innovative technique called immunosignaturing for early cancer detection. Much of the research and funds in the recent years have been directed at the discovery of biomarkers, which serve as pre-symptomatic cancer indicators. According to a previous study, predictive molecular assays can also help increase specificity and efficacy of drugs in treating diseases such as cancer. However, identifying cancer biomarkers requires overcoming a number of hurdles.
  7. Welsh Gov Launches Life Sciences Hub In Wales
    7/18/2014
    The Life Sciences Hub Wales has been set up by the Welsh government as a national and international center for the Life Sciences and Healthcare sectors in Wales.
  8. Immunocore And Lilly Ink Immunotherapy Partnership
    7/18/2014
    Eli Lilly announced that it has signed into a $45 million collaboration deal with privately held clinical stage biotech firm Immunocore. Together, the companies aim to discover and develop novel cancer immunotherapies called ImmTACs.
  9. Lilly Study Suggests Cognitive-Function Impairment Link In AD
    7/17/2014
    Eli Lilly and Co. reported findings from its analyses of five datasets investigating the relationship between cognitive and functional impairment in the progress of mild Alzheimer’s disease. According to the company’s analyses, cognitive decline both precedes and predicts later impairment in function observed in patients with AD. The data were presented at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark.
  10. Ipsen And Galderma Enter Exclusive Partnership In Neurotoxins
    7/17/2014
    Specialty pharmaceutical company Ipsen and global healthcare firm Galderma announced that they have entered into an exclusive partnership to develop and market new neurotoxins, including their liquid formulations. The partners have also extended the scope of their distribution partnership for Dysport/Azzalure in the U.S. and Canada.
Newsletter Signup
Newsletter Signup